P Foro Arnalot1,2,3, O Pera4,5,6, N Rodriguez4,5,6, X Sanz4,5,6, A Reig4,5, I Membrive4,5, A Ortiz4,5, R Granados4,5, M Algara4,5,6. 1. Department of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain. pforo@parcdesalutmar.cat. 2. IMIM (Hospital del Mar Medical Research Institute), Carrer del Dr. Aiguader, 88, 08003, Barcelona, Spain. pforo@parcdesalutmar.cat. 3. Universitat Pompeu Fabra, Barcelona, Spain. pforo@parcdesalutmar.cat. 4. Department of Radiation Oncology, Parc de Salut Mar, Sant Josep de la Montanya 12, 08024, Barcelona, Spain. 5. IMIM (Hospital del Mar Medical Research Institute), Carrer del Dr. Aiguader, 88, 08003, Barcelona, Spain. 6. Universitat Pompeu Fabra, Barcelona, Spain.
Abstract
PURPOSE: To determine if there is an association between the incidental radiation dose to the subventricular zone and survival in patients with glioblastoma multiforme treated with surgery, radiotherapy and temozolomide. METHODS AND MATERIALS: Sixty-five patients, treated between 2006 and 2015, were included in this retrospective study. The doses (75th percentile; p75) administered to the ipsilateral, contralateral and bilateral subventricular zone were compared to overall survival and progression-free survival using Cox proportional hazards models. Covariates included: age, sex, surgery, tumor location, and concomitant and adjuvant temozolomide. RESULTS: Median progression-free survival and overall survival were 11.5 ± 9.96 and 18.8 ± 18.5 months, respectively. The p75 doses to the ipsilateral, contralateral and bilateral subventrivular zone were, respectively, 57.30, 48.8, and 52.7 Gy. Patients who received a dose ≥48.8 Gy in the contralateral subventricular zone had better progression-free survival than those who received lower doses (HR 0.46; 95% CI 0.23-0.91 P = 0.028). This association was not found for overall survival (HR 0.60; 95% CI 0.30-1.22 P = 0.16). Administration of adjuvant temozolomide was significantly associated with improved progression-free survival (HR 0.19; 95% CI 0.09-0.41 P < 0.0001) and overall survival (HR 0.11; 95% CI 0.05-0.24 P = 0.001). In the subgroup of 46 patients whose O6-methylguanine-DNA methyltransferase gene promoter status was known, the methylation had no effect on either progression-free survival (P = 0.491) or overall survival (P = 0.203). CONCLUSION: High-dose radiation in the contralateral subventricular zone was associated with a significant improvement in progression-free survival but not overall survival in patients treated for glioblastoma multiforme.
PURPOSE: To determine if there is an association between the incidental radiation dose to the subventricular zone and survival in patients with glioblastoma multiforme treated with surgery, radiotherapy and temozolomide. METHODS AND MATERIALS: Sixty-five patients, treated between 2006 and 2015, were included in this retrospective study. The doses (75th percentile; p75) administered to the ipsilateral, contralateral and bilateral subventricular zone were compared to overall survival and progression-free survival using Cox proportional hazards models. Covariates included: age, sex, surgery, tumor location, and concomitant and adjuvant temozolomide. RESULTS: Median progression-free survival and overall survival were 11.5 ± 9.96 and 18.8 ± 18.5 months, respectively. The p75 doses to the ipsilateral, contralateral and bilateral subventrivular zone were, respectively, 57.30, 48.8, and 52.7 Gy. Patients who received a dose ≥48.8 Gy in the contralateral subventricular zone had better progression-free survival than those who received lower doses (HR 0.46; 95% CI 0.23-0.91 P = 0.028). This association was not found for overall survival (HR 0.60; 95% CI 0.30-1.22 P = 0.16). Administration of adjuvant temozolomide was significantly associated with improved progression-free survival (HR 0.19; 95% CI 0.09-0.41 P < 0.0001) and overall survival (HR 0.11; 95% CI 0.05-0.24 P = 0.001). In the subgroup of 46 patients whose O6-methylguanine-DNA methyltransferase gene promoter status was known, the methylation had no effect on either progression-free survival (P = 0.491) or overall survival (P = 0.203). CONCLUSION: High-dose radiation in the contralateral subventricular zone was associated with a significant improvement in progression-free survival but not overall survival in patients treated for glioblastoma multiforme.
Entities:
Keywords:
Glioblastoma; Radiotherapy; Subventricular zone
Authors: Percy Lee; Wietse Eppinga; Frank Lagerwaard; Timothy Cloughesy; Benjamin Slotman; Phioanh L Nghiemphu; Pin-Chieh Wang; Patrick Kupelian; Nzhde Agazaryan; John Demarco; Michael T Selch; Michael Steinberg; Jung Julie Kang Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-22 Impact factor: 7.038
Authors: Patrick Evers; Percy P Lee; John DeMarco; Nzhde Agazaryan; James W Sayre; Michael Selch; Frank Pajonk Journal: BMC Cancer Date: 2010-07-21 Impact factor: 4.430
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Timothy J Brown; Matthew C Brennan; Michael Li; Ephraim W Church; Nicholas J Brandmeir; Kevin L Rakszawski; Akshal S Patel; Elias B Rizk; Dima Suki; Raymond Sawaya; Michael Glantz Journal: JAMA Oncol Date: 2016-11-01 Impact factor: 31.777
Authors: Akshitkumar M Mistry; David J Wooten; L Taylor Davis; Bret C Mobley; Vito Quaranta; Rebecca A Ihrie Journal: Sci Rep Date: 2019-02-12 Impact factor: 4.379